Mylan Inc (MYL) 47.81 $MYL
Mylan Earnings In Retrospect: Down 7.2% in the Last 11 Days (MYL)
Comtex SmarTrend(R) - Mon May 12, 10:54AM CDT
When Mylan (NASDAQ:MYL) reported earnings 11 days ago on May 1st, 2014, analysts, on average, expected the company to report earnings of $0.62 on sales of $1.8 billion. The company actually reported EPS of $0.66 on sales of $1.7 billion, beating EPS estimates by $0.04 and missing revenue estimates by $56.6 million. Since the company's report, shares of Mylan have fallen from $49.74 to $46.14, representing a loss of 7.2% in the past 11 days.
Quarterly Earnings Releases and Drug Approval Updates - Analyst Notes on Perrigo, AstraZeneca, Valeant, Aegerion and Mylan
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), AstraZeneca Plc (NYSE: AZN), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2325-100free.
Is This The Next Billion-Dollar Biotech Idea?
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 9:30AM CDT
Developing a new drug costs hundreds of millions of dollars, but for every five drugs that reach the market, another 95 end up in the trash bin . That makes finding the next big thing in biotech particularly hit or miss. Frankly, the odds are...
Mylan (MYL) Approaches New Downside Target of $45.75
Comtex SmarTrend(R) - Fri May 09, 9:35AM CDT
Shares of Mylan (NASDAQ:MYL) opened today below their pivot of $47.80 and have already reached the first level of support at $46.54. Should the shares continue to fall, the support pivots of $45.75 and $43.70 will be of interest.
Mylan to Present at the UBS Global Healthcare Conference
PR Newswire - Fri May 09, 9:30AM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014, in New York. The presentation is scheduled to begin at 10:30 a.m. ET.
Mylan to Present at the BofA Merrill Lynch 2014 Health Care Conference
PR Newswire - Fri May 09, 8:01AM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the BofA Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014, in Las Vegas. The presentation is scheduled to begin at 11:20 a.m. PT.
Is Abbott Laboratories Headed for a Breakup?
Dan Carroll, The Motley Fool - Motley Fool - Wed May 07, 5:30PM CDT
Dealing's back in style in health care's 2014. From major drugmakers looking to sell off slow-growth assets to big pharma's top names hunting for blockbuster acquisitions, the year's been home to no shortage of activity on the mergers and...
Watch for Mylan to Potentially Rebound After Falling 2.83% Yesterday
Comtex SmarTrend(R) - Tue May 06, 4:35PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $48.40 to a high of $49.81. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $48.95 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Mylan After 2.83% Loss
Comtex SmarTrend(R) - Tue May 06, 4:34PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $48.40 to a high of $49.81. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $48.95 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Financial Results, Upcoming Earnings Schedules, New Launches, and Lawsuit Filings - Analyst Notes on AstraZeneca, Boston Scientific, Valeant, Illumina and Mylan
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Boston Scientific Corporation (NYSE: BSX), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Illumina Inc. (NASDAQ: ILMN) and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1970-100free.
Mylan
at Investor's Business Daily - Thu May 01, 5:54PM CDT
Mylan (MYL) Q1 earnings rose 6% to 66 cents a share, beating views by 3 cents. Sales grew 5% to $1.72 bil, shy of analyst consensus for $1.77 bil. Mylan has been pursuing Swedish pharma Meda, which said Mon. it rejected Mylan's latest offer. Mylan...
Mylan Beats on Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:17PM CDT
Mylan (MYL) reported lower-than-expected revenues in the first quarter.
Active Equities to Watch -- Research on Salesforce.com, E-Commerce China Dangdang, Mylan, and Seagate Technology
PR Newswire - Thu May 01, 7:05AM CDT
The trading session on Wednesday, April 30, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,580.84, up 0.27% and the NASDAQ Composite closed at 4,114.56, up 0.27%. The S&P 500 finished the day 0.30% higher at 1,883.95. The gains were broad based as nine out of ten sectors finished on a positive note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Salesforce.com Inc. (NYSE: CRM), E-Commerce China Dangdang Inc. (NYSE: DANG), Mylan Inc. (NASDAQ: MYL) and Seagate Technology PLC (NASDAQ: STX). Free technical research on CRM, DANG, MYL and STX can be downloaded upon signing up at:
Mylan First Quarter 2014 Adjusted Diluted EPS Increases 6% to $0.66
PR Newswire - Thu May 01, 6:00AM CDT
Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2014.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
Exxon, Goldcorp, Royal Gold: How to Trade Thursday's Earnings Reports
at The Street - Wed Apr 30, 9:54AM CDT
Bunge, Cardinal Health, Cigna, Jarden, MasterCard, Mylan, Blue Nile and Textron join Exxon, Goldcorp and Royal Gold in an earnings crowd before the opening bell Thursday.
Generic Drugs Industry Announces Earnings Results, Leadership Appointments, and Conference Participation - Analyst Notes on Mylan, Zoetis, Hospira, Horizon Pharma and The Medicines Co
PR Newswire - Wed Apr 30, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan, Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS), Hospira Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP) and The Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1816-100free.
Could This Be the Next Health Care Acquisition Target?
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 11:05AM CDT
If you follow the health-care sector in any way, shape, or form, the pay week and a half has been nothing short of incredible. Merger and acquisition activity usually comes in spurts, and true megadeals are rare . But in recent days we have been...
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Mylan (MYL) Breaks Through Support at $49.58
Comtex SmarTrend(R) - Mon Apr 28, 1:01PM CDT
Mylan (NASDAQ:MYL) has opened bearishly below the pivot of $51.58 today and has reached the first level of support at $49.58. Should the shares continue to fall, the support pivots of $47.07 and $42.56 will be of interest.
Mylan Earnings In Retrospect: Down 7.2% in the Last 11 Days (MYL)
Comtex SmarTrend(R) - Mon May 12, 10:54AM CDT
When Mylan (NASDAQ:MYL) reported earnings 11 days ago on May 1st, 2014, analysts, on average, expected the company to report earnings of $0.62 on sales of $1.8 billion. The company actually reported EPS of $0.66 on sales of $1.7 billion, beating EPS estimates by $0.04 and missing revenue estimates by $56.6 million. Since the company's report, shares of Mylan have fallen from $49.74 to $46.14, representing a loss of 7.2% in the past 11 days.
Quarterly Earnings Releases and Drug Approval Updates - Analyst Notes on Perrigo, AstraZeneca, Valeant, Aegerion and Mylan
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), AstraZeneca Plc (NYSE: AZN), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2325-100free.
Is This The Next Billion-Dollar Biotech Idea?
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 9:30AM CDT
Developing a new drug costs hundreds of millions of dollars, but for every five drugs that reach the market, another 95 end up in the trash bin . That makes finding the next big thing in biotech particularly hit or miss. Frankly, the odds are...
Mylan (MYL) Approaches New Downside Target of $45.75
Comtex SmarTrend(R) - Fri May 09, 9:35AM CDT
Shares of Mylan (NASDAQ:MYL) opened today below their pivot of $47.80 and have already reached the first level of support at $46.54. Should the shares continue to fall, the support pivots of $45.75 and $43.70 will be of interest.
Mylan to Present at the UBS Global Healthcare Conference
PR Newswire - Fri May 09, 9:30AM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014, in New York. The presentation is scheduled to begin at 10:30 a.m. ET.
Mylan to Present at the BofA Merrill Lynch 2014 Health Care Conference
PR Newswire - Fri May 09, 8:01AM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the BofA Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014, in Las Vegas. The presentation is scheduled to begin at 11:20 a.m. PT.
Is Abbott Laboratories Headed for a Breakup?
Dan Carroll, The Motley Fool - Motley Fool - Wed May 07, 5:30PM CDT
Dealing's back in style in health care's 2014. From major drugmakers looking to sell off slow-growth assets to big pharma's top names hunting for blockbuster acquisitions, the year's been home to no shortage of activity on the mergers and...
Watch for Mylan to Potentially Rebound After Falling 2.83% Yesterday
Comtex SmarTrend(R) - Tue May 06, 4:35PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $48.40 to a high of $49.81. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $48.95 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Mylan After 2.83% Loss
Comtex SmarTrend(R) - Tue May 06, 4:34PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $48.40 to a high of $49.81. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $48.95 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Financial Results, Upcoming Earnings Schedules, New Launches, and Lawsuit Filings - Analyst Notes on AstraZeneca, Boston Scientific, Valeant, Illumina and Mylan
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Boston Scientific Corporation (NYSE: BSX), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Illumina Inc. (NASDAQ: ILMN) and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1970-100free.
Mylan
at Investor's Business Daily - Thu May 01, 5:54PM CDT
Mylan (MYL) Q1 earnings rose 6% to 66 cents a share, beating views by 3 cents. Sales grew 5% to $1.72 bil, shy of analyst consensus for $1.77 bil. Mylan has been pursuing Swedish pharma Meda, which said Mon. it rejected Mylan's latest offer. Mylan...
Mylan Beats on Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:17PM CDT
Mylan (MYL) reported lower-than-expected revenues in the first quarter.
Active Equities to Watch -- Research on Salesforce.com, E-Commerce China Dangdang, Mylan, and Seagate Technology
PR Newswire - Thu May 01, 7:05AM CDT
The trading session on Wednesday, April 30, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,580.84, up 0.27% and the NASDAQ Composite closed at 4,114.56, up 0.27%. The S&P 500 finished the day 0.30% higher at 1,883.95. The gains were broad based as nine out of ten sectors finished on a positive note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Salesforce.com Inc. (NYSE: CRM), E-Commerce China Dangdang Inc. (NYSE: DANG), Mylan Inc. (NASDAQ: MYL) and Seagate Technology PLC (NASDAQ: STX). Free technical research on CRM, DANG, MYL and STX can be downloaded upon signing up at:
Mylan First Quarter 2014 Adjusted Diluted EPS Increases 6% to $0.66
PR Newswire - Thu May 01, 6:00AM CDT
Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2014.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
Exxon, Goldcorp, Royal Gold: How to Trade Thursday's Earnings Reports
at The Street - Wed Apr 30, 9:54AM CDT
Bunge, Cardinal Health, Cigna, Jarden, MasterCard, Mylan, Blue Nile and Textron join Exxon, Goldcorp and Royal Gold in an earnings crowd before the opening bell Thursday.
Generic Drugs Industry Announces Earnings Results, Leadership Appointments, and Conference Participation - Analyst Notes on Mylan, Zoetis, Hospira, Horizon Pharma and The Medicines Co
PR Newswire - Wed Apr 30, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan, Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS), Hospira Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP) and The Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1816-100free.
Could This Be the Next Health Care Acquisition Target?
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 11:05AM CDT
If you follow the health-care sector in any way, shape, or form, the pay week and a half has been nothing short of incredible. Merger and acquisition activity usually comes in spurts, and true megadeals are rare . But in recent days we have been...
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Mylan (MYL) Breaks Through Support at $49.58
Comtex SmarTrend(R) - Mon Apr 28, 1:01PM CDT
Mylan (NASDAQ:MYL) has opened bearishly below the pivot of $51.58 today and has reached the first level of support at $49.58. Should the shares continue to fall, the support pivots of $47.07 and $42.56 will be of interest.
